World Health Organization Raises Warning Over Acute Lack of Obesity Injections

Fewer than a tenth of patients eligible to benefit from weight-loss injections such as Wegovy are able to get them, warns the WHO as it releases its initial advice on the therapies.

Considering in excess of 1,000,000,000 people worldwide now obese, it is calling for increased and just availability to GLP-1 medication.

Per estimates, in excess of 2,000,000,000 will be living with obesity by 2030 if no action is taken.

"Our latest guidance affirms that obesity is a long-term condition that can be treated with comprehensive and lifelong care," stated the agency's head Tedros Adhanom Ghebreyesus.

Significant expense, insufficient output, and supply-chain constraints are major barriers to universal access to the jabs that can aid individuals in losing significant weight, notes the body.

GLP-1 Therapy Shortage

Even in the current best projected scenario, the production of such drugs could only cover around 100 million people – fewer than 10% of those who need them, as stated by the health organization.

The advice encourages nations and manufacturers to widen availability, via approaches including voluntary licensing.

A patent on a key compound – the main ingredient of a leading brand – is scheduled to end in several countries in 2026.

The Way Obesity Injections Work

The injections mimick a body's own hormone to delay gastric emptying, reduce hunger and increase the sense of being full so individuals eat less.

People usually see weight reduction in the initial weeks of starting on the once-weekly jabs.

Research indicates patients may regain a significant portion a year later of discontinuing the drug, because their typical appetite come back.

To be carrying excess weight elevates your chance for experiencing diseases, like diabetes, cardiovascular issues, stroke, and some malignancies.

Obesity affects people in every country and was associated with 3.7 million deaths worldwide in 2024, according to the health agency.